NRIX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
673.1M
+7342.9%
9.0M
+44.6%
6.3M
-54.0%
13.6M
+72.0%
7.9M
Cost of Revenue
0
0
0
0
0
Gross Profit
673.1M
+7342.9%
9.0M
+44.6%
6.3M
-54.0%
13.6M
+72.0%
7.9M
Operating Expenses
113.6M
+10.0%
103.2M
+4.6%
98.7M
+2.1%
96.7M
-2.6%
99.3M
R&D
79.3M
-9.6%
87.7M
+4.2%
84.1M
+1.3%
83.0M
-3.6%
86.1M
SG&A
34.4M
+120.3%
15.6M
+6.7%
14.6M
+7.0%
13.6M
+3.7%
13.2M
Operating Income
559.5M
+693.9%
-94204000
-1.8%
-92495000
-11.3%
-83095000
+9.1%
-91385000
EBITDA
561.6M
+710.8%
-91949000
-1.8%
-90299000
-11.5%
-80975000
+9.4%
-89357000
Net Income
549.8M
+714.1%
-89535000
-2.7%
-87174000
-11.4%
-78221000
+9.5%
-86421000
EPS (Basic)
$4.93
+708.6%
$-0.81
-2.5%
$-0.79
+3.7%
$-0.82
+20.4%
$-1.03
EPS (Diluted)
$4.73
+684.0%
$-0.81
-2.5%
$-0.79
+3.7%
$-0.82
+20.4%
$-1.03
Shares (Diluted)
116.2M
+4.6%
111.1M
+0.9%
110.1M
+15.8%
95.1M
+13.0%
84.2M
Nurix Therapeutics (NRIX) โ€” Financials